Dr. Saab on Immunotherapy in MSI-H GI Malignancies

Tanios Bekaii-Saab, MD
Published: Friday, Sep 22, 2017



Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.

Patients whose disease lacks the expression of some proteins would be classified as MSI-H, which is found in 4% of patients. This is a surrogate marker for tumors that are loaded with mutations, states Bekaii-Saab.

The presence of MSI-H phenotype is dependent on 2 elements. Firstly, it could be acquired through the genetics of the patient. Secondly, patients could acquire this sporadically, which is the majority of patients in the metastatic setting.
 


Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.

Patients whose disease lacks the expression of some proteins would be classified as MSI-H, which is found in 4% of patients. This is a surrogate marker for tumors that are loaded with mutations, states Bekaii-Saab.

The presence of MSI-H phenotype is dependent on 2 elements. Firstly, it could be acquired through the genetics of the patient. Secondly, patients could acquire this sporadically, which is the majority of patients in the metastatic setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x